Amrize (NYSE:AMRZ) Given New $46.00 Price Target at UBS Group

Amrize (NYSE:AMRZ – Get Free Report) had its target price hoisted by UBS Group from $42.00 to $46.00 in a research report issued on Monday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group‘s price objective indicates a potential upside of 14.08% from the stock’s previous close.

Several other research analysts also recently issued reports on AMRZ. Bank of America downgraded Amrize from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $50.00 to $40.00 in a report on Wednesday, September 2nd. Oppenheimer lowered their target price on Amrize from $55.00 to $52.00 and set an “outperform” rating for the company in a research note on Monday, November 2nd. Truist Financial dropped their target price on Amrize from $48.00 to $35.00 and set a “hold” rating for the company in a research report on Monday, October 5th. Berenberg Bank downgraded Amrize from a “buy” rating to a “hold” rating and dropped their target price for the stock from $48.00 to $46.00 in a research report on Monday, November 9th. Finally, Deutsche Bank cut their price target on Amrize from $64.00 to $56.00 and set a “buy” rating on the stock in a research note on Wednesday, September 23rd. Eight research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $47.18.

Get Our Latest Research Report on AMRZ

Amrize Price Performance

Shares of AMRZ stock traded down $0.57 during trading hours on Monday, reaching $40.32. 699,399 shares of the company were exchanged, compared to its average volume of 3,454,077. Amrize has a fifty-two week low of $35.78 and a fifty-two week high of $65.94. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.07 and a quick ratio of 0.67. The stock’s fifty day moving average is $39.33 and its two-hundred day moving average is $49.98. The company has a market cap of $22.30 billion, a price-to-earnings ratio of 18.24, a P/E/G ratio of 1.60 and a beta of 0.03.

Amrize (NYSE:AMRZ – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported $1.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.05. The business had revenue of $3.77 billion during the quarter. Amrize had a net margin of 9.93% and a return on equity of 10.02%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.98 EPS. Sell-side analysts forecast that Amrize will post 2.30 earnings per share for the current fiscal year.

Insider Transactions at Amrize

In related news, Director Jacques Sanche bought 4,150 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $45.02 per share, with a total value of $186,833.00. Following the completion of the purchase, the director owned 9,766 shares of the company’s stock, valued at $439,665.32. This represents a 73.90% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jan Jenisch bought 4,000 shares of Amrize stock in a transaction on Wednesday, September 2nd. The shares were bought at an average price of $42.50 per share, for a total transaction of $170,000.00. Following the acquisition, the chief executive officer owned 519,000 shares of the company’s stock, valued at approximately $22,057,500. The trade was a 0.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 34,155 shares of company stock valued at $1,461,276 in the last quarter. 0.54% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AMRZ. Pictet Asset Management Holding SA raised its holdings in Amrize by 4.3% during the 3rd quarter. Pictet Asset Management Holding SA now owns 6,126,150 shares of the company’s stock worth $230,110,000 after buying an additional 253,512 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Amrize by 10.4% in the first quarter. Renaissance Technologies LLC now owns 1,956,600 shares of the company’s stock valued at $109,609,000 after buying an additional 183,900 shares during the period. Amundi increased its position in shares of Amrize by 30.9% during the first quarter. Amundi now owns 1,654,739 shares of the company’s stock worth $92,698,000 after acquiring an additional 390,750 shares in the last quarter. Swiss National Bank increased its position in shares of Amrize by 7.1% during the first quarter. Swiss National Bank now owns 1,460,874 shares of the company’s stock worth $81,838,000 after acquiring an additional 96,800 shares in the last quarter. Finally, National Pension Service increased its position in shares of Amrize by 7.5% during the second quarter. National Pension Service now owns 1,493,022 shares of the company’s stock worth $79,578,000 after acquiring an additional 103,962 shares in the last quarter.

Amrize Company Profile

(Get Free Report)

Amrize is a North American building materials and construction solutions company serving customers across the United States and Canada. Its operations span the construction materials and building envelope markets. The company supplies cement, aggregates, ready-mix concrete and asphalt, as well as roofing and other building-envelope products and services. These materials and solutions support residential, commercial and infrastructure projects. Amrize became an independent publicly traded company in 2025 through the spin-off of Holcim’s North American business.

Further Reading

Analyst Recommendations for Amrize (NYSE:AMRZ)

Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.